Compare AFYA & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFYA | DBVT |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | Brazil | France |
| Employees | N/A | 90 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2019 | 2014 |
| Metric | AFYA | DBVT |
|---|---|---|
| Price | $13.42 | $22.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $17.00 | ★ $31.75 |
| AVG Volume (30 Days) | 90.3K | ★ 244.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,151,000.00 |
| Revenue This Year | $14.67 | $1,768.71 |
| Revenue Next Year | $7.84 | $1,028.88 |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.12 | $3.82 |
| 52 Week High | $19.76 | $26.19 |
| Indicator | AFYA | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 31.69 | 58.09 |
| Support Level | N/A | $20.11 |
| Resistance Level | $15.35 | $25.52 |
| Average True Range (ATR) | 0.40 | 1.38 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 10.95 | 69.51 |
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.